The Role of Hypoxia in Endometrial Cancer
- 1 February 2022
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 23 (2), 221-234
- https://doi.org/10.2174/1389201022666210224130022
Abstract
Endometrial cancer represents the most frequent neoplasia from the corpus uteri, and comprises the 14th leading cause of death in women worldwide. Risk factors that contribute to the disease include early menarche, late menopause, nulliparity, and menopausal hormone use, as well as hypertension and obesity comorbidities. The clinical effectiveness of chemotherapy is variable, suggesting that novel molecular targeted therapies against specific cellular processes associated with the maintenance of cancer cell survival and therapy resistance urged to ameliorate the rates of success in endometrial cancer treatment. In the course of tumor growth, cancer cells must adapt to decreased oxygen availability in the microenvironment by upregulation of hypoxia-inducible factors, which orchestrate the activation of a transcriptional program leading to cell survival. During this adaptative process, the hypoxic cancer cells may acquire invasive and metastatic properties as well as increased cell proliferation and resistance to chemotherapy, enhanced angiogenesis, vasculogenic mimicry, and maintenance of cancer cell stemness, which contribute to more aggressive cancer phenotypes. Several studies have shown that hypoxia-inducible factor 1 alpha (HIF-1α) protein is aberrantly overexpressed in many solid tumors from breast, prostate, ovarian, bladder, colon, brain, and pancreas. Thus, it has been considered an important therapeutic target. Here, we reviewed the current knowledge of the relevant roles of cellular hypoxia mechanisms and HIF-1α functions in diverse processes associated with endometrial cancer progression. In addition, we also summarize the role of microRNAs in the posttranscriptional regulation of protein-encoding genes involved in the hypoxia response in endometrial cancer. Finally, we pointed out the need for urgent targeted therapies to impair the cellular processes activated by hypoxia in the tumor microenvironment.Keywords
Funding Information
- Consejo Nacional de Ciencia y Tecnología CONACYT (A1-S-13656)
This publication has 102 references indexed in Scilit:
- Germline and somatic polymerase ϵ and δ mutations define a new class of hypermutated colorectal and endometrial cancersThe Journal of Pathology, 2013
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012
- Hypoxia-Inducible Factors in Physiology and MedicineCell, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participantsThe Lancet, 2011
- Cancer Cell Invasion: Treatment and Monitoring Opportunities in NanomedicineAdvanced Drug Delivery Reviews, 2011
- Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase PathwayMolecular Cell, 2008
- Regulation of angiogenesis by hypoxia: role of the HIF systemNature Medicine, 2003
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- The Hallmarks of CancerCell, 2000